[PDF] Top 20 Rev. Bras. Hematol. Hemoter. vol.38 número4
Has 10000 "Rev. Bras. Hematol. Hemoter. vol.38 número4" found on our website. Below are the top 20 most common "Rev. Bras. Hematol. Hemoter. vol.38 número4".
Rev. Bras. Hematol. Hemoter. vol.38 número4
... Professor Michel Abu Jamra was born on August 13, 1916. Dur- ing the 10th Recycling Course of Hematology and Transfusion Medicine of Hospital Israelita Albert Einstein held in conjunc- t[r] ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.38 número4
... Therapeutic role of alemtuzumab (campath-1h) in patients who have failed fludarabine: results of a large international study. Lozanski G, Heerema NA, Flinn IW, Smith L, Harbison J, Webb [r] ... See full document
13
Rev. Bras. Hematol. Hemoter. vol.38 número4
... 14 The primary objec- tive of this study was to determine whether the collection of progenitor cells using G-CSF alone is sufficient to per- form at least one ASCT, compared with a group[r] ... See full document
8
Rev. Bras. Hematol. Hemoter. vol.38 número4
... This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )... 372 rev bras hematol hemoter.[r] ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.38 número4
... In our cohort, BMMSCs from de novo AML presented increased CDKN1A mRNA levels compared to healthy donors, MDS and AML-MRC patients ( p -value <0.05; Figure 1 A).. TP53 expression was [r] ... See full document
3
Rev. Bras. Hematol. Hemoter. vol.38 número4
... Stroke-like encephalopathy is a rare MTX neurotoxicity that manifests with sudden onset of focal neurological deficits, such as hemiparesis, that occur days to weeks after MTX administra[r] ... See full document
4
Rev. Bras. Hematol. Hemoter. vol.38 número4
... An unusual difficulty in blood grouping due to soluble group substance in a patient’s serum.[r] ... See full document
3
Rev. Bras. Hematol. Hemoter. vol.38 número4
... Herein we report our experience treating a Jehovah’s Wit- ness using vinblastine, low dose Ara-C and valproic acid but without blood transfusions, based on a treatment for elderly patien[r] ... See full document
3
Rev. Bras. Hematol. Hemoter. vol.38 número4
... The recommended treatment for beta-thalassemia major involves regular red blood cell transfusions through- out life, usually administered every two to five weeks depending on the transfu[r] ... See full document
5
Rev. Bras. Hematol. Hemoter. vol.38 número4
... The histo-blood group carbohydrates synthesized from type 2 precursor oligosaccharides are intrinsic to the red blood cell membrane as they are expressed by red blood cell precur- sor ce[r] ... See full document
10
Rev. Bras. Hematol. Hemoter. vol.38 número4
... Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose or oral iron as preoperative treatment in patients with colon cancer and iron deficiency anaemia.[r] ... See full document
6
Rev. Bras. Hematol. Hemoter. vol.38 número4
... Methods: A cohort of 91 Brazilian MDS patients, including patients with ring sideroblasts in the bone marrow, were screened for mutations in the SF3B1 hotspots (exons 12–15) by direct Sa[r] ... See full document
5
Rev. Bras. Hematol. Hemoter. vol.38 número4
... Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.. Biol Blood Marrow Transpl.[r] ... See full document
6
Rev. Bras. Hematol. Hemoter. vol.38 número4
... et al. The immature platelet fraction is a useful marker for predicting the timing of platelet recovery in patients with cancer after chemotherapy and hematopoietic stem cell transplantation. Int J Lab Hematol. ... See full document
4
Rev. Bras. Hematol. Hemoter. vol.38 número4
... The present study therefore aims to evaluate the incidence of infection by the herpes virus in patients submitted to autologous HSCT in respect to the early suspension of acyclovir.. Met[r] ... See full document
4
Rev. Bras. Hematol. Hemoter. vol.38 número4
... Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chem[r] ... See full document
6
Rev. Bras. Hematol. Hemoter. vol.38 número4
... The immature retic- ulocyte fraction (IRF) provides the same information obtained by the reticulocyte count regarding the evaluation of bone mar- row response to anemia or erythropoietic[r] ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.38 número4
... 5. Crusoe EQ, Higashi F, Martinez GA, Barros JC, Bellesso M, Rossato M, et al. Is it feasible to use granulocyte-colony stimulating factor alone to mobilize progenitor cells in multiple myeloma patients induced with a ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.38 número4
... Acute myeloid leukemia cases with hemophagocytosis by blast cells were reviewed to investigate the presence of the MYST3-CREBBP fusion gene by fluorescence in situ hybridization (FISH) a[r] ... See full document
7
Rev. Bras. Hematol. Hemoter. vol.38 número4
... Splicing factor SF3B1 mutations and ring sideroblasts in myelodysplastic syndromes: a Brazilian cohort screening study. Rev Bras Hematol Hemoter[r] ... See full document
2
temas relacionados